Background: Erythropoietin stimulating agents (ESAs) are high-cost medications that have a significant impact on many pharmacy budgets. Recently, ESAs have received stronger safety warnings and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback